Sandbox:Sahar: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 5: | Line 5: | ||
{{Family tree/start}} | {{Family tree/start}} | ||
{{Family tree | | | | | | | | | | | | A01 | | | |A01= Patient with | {{Family tree | | | | | | | | | | | | A01 | | | |A01= Patient with carotid body tumor}} | ||
{{Family tree | | | | | | | | | | | | |!| | | | | }} | {{Family tree | | | | | | | | | | | | |!| | | | | }} | ||
{{Family tree | | | | | | | | | | | | B01 | | | |B01= History, Physical examination, and evaluation of cnotralateral side}} | {{Family tree | | | | | | | | | | | | B01 | | | |B01= History, Physical examination, and evaluation of cnotralateral side}} | ||
{{Family tree | | | | | | | | | |,|-|-|^|-|-|.| | }} | {{Family tree | | | | | | | | | |,|-|-|^|-|-|.| | }} | ||
{{Family tree | | | | | | | | | C01 | | | | C02 |C01= Patients with age < 50 years<br>Patients with multiple paraganglioma<br>Patients with a positive family history| C02= The rest of the patients}} | {{Family tree | | | | | | | | | C01 | | | | C02 |C01= Patients with age < 50 years<br>Patients with multiple paraganglioma<br>Patients with a positive family history| C02= The rest of the patients}} | ||
{{Family tree | | | | | | | | | |! | {{Family tree | | | | | | | | | |!| | | | }} | ||
{{Family tree | | | | | | | | | D01 | | | |D01= SDHD genetic testing}} | {{Family tree | | | | | | | | | D01 | | | | | |D01= SDHD genetic testing}} | ||
{{Family tree | | | | | | | | {{Family tree | | | | | |,|-|-|-|^|-|-|.| | }} | ||
{{Family tree | | | | | | | {{Family tree | | | | | E01 | | | | | E02 |E01= Presence of SDHD mutation |E02= Absence of SDHD mutation}} | ||
{{Family tree | | | | | | | | {{Family tree | | | | | |!| | | | | | |!| | | | | }} | ||
{{Family tree | | | | | | | | {{Family tree | | | | | |!| | | | | | F01 | | | |F01= SDHC and SDHB genetic testing}} | ||
{{Family tree | | | | | | | | {{Family tree | | | | | |!| | | |,|-|-|^|-|-|.| | }} | ||
{{Family tree | | | | | | | | {{Family tree | | | | | |!| | | G01 | | | | G02 |G01= Presence of SDHC/B mutation |G02= Absence of SDHC/B mutation}} | ||
{{Family tree | | | | | | | | {{Family tree | | | | | |!| | | |!| | }} | ||
{{familytree | | | | | | H02 |'| | | |H02=All the relatives should be evaluated for the presence of paragnaglioma}} | {{familytree | | | | | | H02 |-|'| | | |H02=All the relatives should be evaluated for the presence of paragnaglioma}} | ||
{{Family tree | | | | | | |!| | | | }} | {{Family tree | | | | | | |!| | | | }} | ||
{{Family tree | | | | | | I01 | | | |I01= whole-body 18F-dihydroxyphenylalanine (F-DOPA) positron emission tomography to assess the presence of other paragangliomas}} | {{Family tree | | | | | | I01 | | | |I01= whole-body 18F-dihydroxyphenylalanine (F-DOPA) positron emission tomography to assess the presence of other paragangliomas}} | ||
{{Family tree | | | |,|-|-|^|-|-|.| |}} | {{Family tree | | | |,|-|-|^|-|-|.| |}} | ||
{{Family tree | | | J01| | {{Family tree | | | J01 | | | | J02 |J01= Presence of other paraganglioma |J02= Absence of other paraganglioma}} | ||
{{Family tree | | | |!| | | | | |!| | | }} | |||
{{Family tree | | | K01 | | | | K02 |K01= 24-hour urine catecholamines and MRI for biochemical screening|K02=surveillance screening every 5 years}} | |||
{{Family tree/end}} | {{Family tree/end}} | ||
Revision as of 15:56, 8 April 2019
| Patient with carotid body tumor | |||||||||||||||||||||||||||||||||||
| History, Physical examination, and evaluation of cnotralateral side | |||||||||||||||||||||||||||||||||||
| Patients with age < 50 years Patients with multiple paraganglioma Patients with a positive family history | The rest of the patients | ||||||||||||||||||||||||||||||||||
| SDHD genetic testing | |||||||||||||||||||||||||||||||||||
| Presence of SDHD mutation | Absence of SDHD mutation | ||||||||||||||||||||||||||||||||||
| SDHC and SDHB genetic testing | |||||||||||||||||||||||||||||||||||
| Presence of SDHC/B mutation | Absence of SDHC/B mutation | ||||||||||||||||||||||||||||||||||
| All the relatives should be evaluated for the presence of paragnaglioma | |||||||||||||||||||||||||||||||||||
| whole-body 18F-dihydroxyphenylalanine (F-DOPA) positron emission tomography to assess the presence of other paragangliomas | |||||||||||||||||||||||||||||||||||
| Presence of other paraganglioma | Absence of other paraganglioma | ||||||||||||||||||||||||||||||||||
| 24-hour urine catecholamines and MRI for biochemical screening | surveillance screening every 5 years | ||||||||||||||||||||||||||||||||||